nov-002 and Tuberculosis--Pulmonary

Surgery results in the development of secondary immunodeficiency associated with inhibition of the phagocytic bactericidal systems, leading to postoperative complications. Glutoxim, a representative of thiopoietins, was used to reduce the number of postoperative complications. Twenty-nine patients with pulmonary tuberculosis received glutoxim therapy (a study group). A control group comprised 25 patients. A course of glutoxim therapy was 35 days; the daily dose was 60 mg. Postoperative complications (tuberculous pleural empyema with bronchopleural fistula, progressive tuberculosis, nonspecific pneumonias) developed in 2 (6.9%) study group patients and in 8 (32%) control ones (p < 0.05). The inclusion ofglutoxim into complex preoperative preparation and its postoperative use cause a significant reduction in postoperative complications.

Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Oligopeptides; Postoperative Complications; Preoperative Care; Tuberculosis, Pulmonary

Drug resistance in Mycobacterium tuberculosis, adverse reactions, caused by antituberculous drugs, as well as suppressed cellular immunity are responsible for lower efficiency of treatment. To improve the results of treatment in patients with tuberculosis in the intensive phase, the authors used glutoxim, a representative of thiopoeitins. Glutoxim treatment was performed in 73 patients with pulmonary tuberculosis (a study group). A control group comprised 45 patients. The course of therapy with glutoxim, 60 mg/day, was 52 days. The study group was characterized by a rapider cessation of intoxication symptoms, the higher rates of bacterial isolation cessation, and decay cavity-closure. At the end of an intensive treatment, there was abacillarity in 64 (86.7%) patients from the study group and in 32 (71.1%) control patients; decay cavity closure was observed in 60 (88.3%) and 29 (70.8%) patients, respectively (p < 0.05).

Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Immunologic Factors; Male; Middle Aged; Oligopeptides; Treatment Outcome; Tuberculosis, Pulmonary

The authors used their immunological correction method to treat 154 patients with progressive pulmonary tuberculosis. Of them, 38 patients received standard antituberculosis therapy (Group 1), 39 had additionally paravasal lymphotrophic immunological correction (Group 2), and 38 took antituberculous drugs in accordance with individual regimens (Group 3), and 39 patients were treated by individual regimens during immunological correction (Group 4). After termination of the basic course of chemotherapy, clinical cure was achieved in 61.1, 76.3, 72.2, and 94.7%, respectively (p < 0.05). During the basic course, mortality was 11.1, 5.3, and 5.5% in the first three groups. By taking into account the immunological status of patients with caseous pneumonia, disseminated, and multicavernous pulmonary tuberculous lesion, immunological correction is indicated early in the basic course of therapy.

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunity, Cellular; Infant; Middle Aged; Oligopeptides; T-Lymphocytes; Thymus Hormones; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary

Results of Glutoxim investigation are presented. Glutoxim is the the drug of the new class--thiopoietins. It is considered to be immunorehabilitator as it modulates intracellular process of thiols metabolism, initiates cytokins system, activates phagocytosis etc. Results of the glutoxim administration at the 42 patients with tuberculosis using traditional treatment regimes are presented. Results of the randomized study at the patients with severe disseminated drug-sensitive and drug-resistant pulmonary tuberculosis demonstrated high efficacy of the glutoxim and its good tolerability. Glutoxim administration allowed to shorten the period of tuberculosis intoxication signs disappearance, to shorten the period of sputum negativation and shortened the period of pulmonary inflammation reverse process. Glutoxim application was specially favorable at the patients with severe tuberculosis complicated by viral or medicamental hepatitis.

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Resistance, Bacterial; Hepatitis, Viral, Human; Humans; Middle Aged; Oligopeptides; Tuberculosis, Pulmonary

The paper deals with the effect of glutoxim included into a preoperative preparation regimen on immunological parameters in patients with fibrocavernous pulmonary tuberculosis. On admission, all the patients had inadequate cellular immunity and activated humoral immunity. After termination of a course of glutoxim therapy, there was an increase in the baseline low values of lymphocytic proliferative activity, in the count of mature T lymphocytes, and in the production of IL-2 induced by phytohemagglutinin. At the same time the similar parameters remained unchanged in the control group. The drug exerted the most noticeable stimulating effect on cellular immunity in patients with a limited process. Glutoxim produced no noticeable effect on humoral immunity. The immunomodulating effect of glutoxim was followed by improvement of the clinical and X-ray pictures of the disease. In glutoxim-treated patients with baseline immunological disorders, progression was found to occur 1.5-2 times more infrequently than in the control group. Indications for the use of glutoxim in the treatment of tuberculosis are specified on the basis of the baseline immunological parameters of each patient.

Topics: Adult; Antigens, CD; Cytokines; Female; Humans; Male; Middle Aged; Oligopeptides; Tuberculosis, Pulmonary